Indeed, the currently most successful therapeutic approach based on metabolic reprogramming regards the inhibitors of the mutant IDH1/2 [82,83,84,85], which are being used to treat acute myeloid leukemia patients, as well as gliomas and other solid cancers, such as cholangiocarcinoma and chondrosarcoma [15]. Here, IDH1 is linked to cholangiocarcinoma.